Cabaletta Bio, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDCabaletta Bio, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 79), indicating performance broadly in line with the market. Earnings growth of 37% provides fundamental context to the price action. Investors should exercise caution due to high volatility (113% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.25 | +14.92% | ABOVE |
| 50 SMA | $3.13 | +19.07% | ABOVE |
| 100 SMA | $2.81 | +32.60% | ABOVE |
| 150 SMA | $2.72 | +37.23% | ABOVE |
| 200 SMA | $2.47 | +50.85% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CABA in an uptrend right now?
CABA has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, CABA is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is CABA overbought or oversold?
CABA's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is CABA outperforming the market?
CABA has a Relative Strength (RS) Rating of 79 out of 99. CABA is performing about average compared to the market.
Where is CABA in its 52-week range?
CABA is trading at $3.73, which is 88% of its 52-week high ($4.23) and 84% above its 52-week low ($1.11).
How volatile is CABA?
CABA has a Beta of 2.54 and 52-week volatility of 113%. It's more volatile than the S&P 500 - expect bigger swings.